- Home
- HNVR vs GOSS Comparison
HNVR vs GOSS Comparison
Compare HNVR & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- GOSS
- Stock Information
- Founded
- HNVR 2008
- GOSS 2015
- Country
- HNVR United States
- GOSS United States
- Employees
- HNVR N/A
- GOSS N/A
- Industry
- HNVR Commercial Banks
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- HNVR Finance
- GOSS Health Care
- Exchange
- HNVR Nasdaq
- GOSS Nasdaq
- Market Cap
- HNVR 163.2M
- GOSS 188.6M
- IPO Year
- HNVR 2022
- GOSS 2019
- Fundamental
- Price
- HNVR $20.70
- GOSS $0.84
- Analyst Decision
- HNVR Buy
- GOSS Strong Buy
- Analyst Count
- HNVR 1
- GOSS 4
- Target Price
- HNVR $22.00
- GOSS $7.50
- AVG Volume (30 Days)
- HNVR 15.1K
- GOSS 1.5M
- Earning Date
- HNVR 04-29-2025
- GOSS 05-06-2025
- Dividend Yield
- HNVR 1.95%
- GOSS N/A
- EPS Growth
- HNVR N/A
- GOSS N/A
- EPS
- HNVR 1.66
- GOSS N/A
- Revenue
- HNVR $63,491,000.00
- GOSS $114,701,000.00
- Revenue This Year
- HNVR N/A
- GOSS N/A
- Revenue Next Year
- HNVR $15.80
- GOSS $172.31
- P/E Ratio
- HNVR $12.47
- GOSS N/A
- Revenue Growth
- HNVR 5.04
- GOSS N/A
- 52 Week Low
- HNVR $13.62
- GOSS $0.50
- 52 Week High
- HNVR $27.14
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- HNVR 46.68
- GOSS 37.58
- Support Level
- HNVR $18.60
- GOSS $0.80
- Resistance Level
- HNVR $21.05
- GOSS $0.88
- Average True Range (ATR)
- HNVR 1.22
- GOSS 0.10
- MACD
- HNVR 0.08
- GOSS -0.01
- Stochastic Oscillator
- HNVR 50.00
- GOSS 20.24
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.